Slide 1: Q2/H1 2024 Results
BioSyent BioSyentInc. Inc. Q4 / FY 2023 Q2/H1 2024 Results Results MARCH AUGUST13, 26,2024 2024 PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX 3 | www.biosyent.com | TSXV: RX
Slide 4: Q2/H1 2024 Sales Summary ($)
Q2/H1 2024 Sales Summary ($) Q2’24 Q2 ‘24 vs. H1’24 H1 ‘24 vs. Sales ($) Q2 ’23 (%) Sales ($) H1 ’23 (%) Canadian Pharma ($) $8,535k +11% $16,082k +14% FeraMAX® Pd +7% +11% RepaGyn® +8% +16% Tibella® +40% +36% Combogesic® +77% +100% Inofolic® n/a n/a Cathejell® +5% +3% Gelclair® n/a n/a Internationa
Slide 5: Sales, EBITDA and NIAT (Q2)
Sales, EBITDA and NIAT Quarter (Q2) ended June 30th +12% 9,000 +20% Record Quarterly Revenue 8,000 +35% 7,000 6,000 5,000 CAD (000's) 4,000 3,000 +10% +10% 2,000 +22% +7% 1,000 7,963 1,860 1,483 8,945 2,048 1,580 0 Q2 2023 Q2 2024 Sales EBITDA NIAT 5 | www.biosyent.com | TSXV: RX
Slide 6: Sales, EBITDA and NIAT (H1)
Sales, EBITDA and NIAT First Half (H1) ended June 30th 18,000 +15% Sales + $1,948k Canadian Pharma 16,000 +6% +35% + $157k International Pharma + $127k Legacy 14,000 12,000 EBITDA / NIAT • EBITDA Margin 10,000 H1 2024: 25% to Sales CAD (000's) H1 2023: 23% to Sales 8,000 • NIAT Margin 6,000 -14% +26
Slide 7: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS 56 Consecutive Profitable Quarters Q2 2024 $1,580,289 $0.13 to Q2 2024 Q1 2024 $1,768,727 $0.15 $0.60 TTM Q4 2023 $1,450,791 $0.12 Q3 2023 $2,350,900 $0.20 Q2 2023 $1,483,190 $0.12 Q1 2023 $1,175,246 $0.10 $0.43 TTM Q4 2022 $1,199,516 $0.09 Q
Slide 8: 2024 YTD Highlights
2024 YTD Highlights Mar/Jun 2024: Quarterly dividends of $0.045 paid (+12.5% increase) Feb 2024: BioSyent named to 2024 TSX Venture 50 Apr 2024: FeraMAX® named #1 recommended iron supplement in Canada for ninth consecutive year Apr 2024: Extension of RepaGyn® and Proktis-M® Agreement to 2032
Slide 9: 2024 YTD Highlights (Continued)
2024 YTD Highlights (Continued) Jun 2024: In-licensing of new endocrinology product for Canada Aug 2024: Declaration of Q3 2024 dividend of $0.045/share Jan – Jun 2024: 162,300 shares repurchased and cancelled under NCIB 9 | www.biosyent.com | TSXV: RX
Slide 10: Most recommended iron supplement in Canada
9 Most recommended iron supplement in Canada - pharmacists and physicians - 9 consecutive years(1) Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2024 Survey on OTC Counselling and Recom
Slide 11: FeraMAX LifeCycle Strategy: Iron health for life
FeraMAX® LifeCycle Strategy Expanding leadership of FeraMAX® brand in Canada: “Iron health for life” FeraMAX® Pd platform introduced in October 2020 Patented delivery system based on Polydextrose Iron Complex (PDIC) FeraMAX® Pd Therapeutic 150 launched Nov 2020 FeraMAX® Pd Powder 15 launch
Slide 12: Growth Drivers
Growth Drivers New endocrinology asset FeraMAX® Pd Platform – Life Cycle Strategy In development HRT agent for menopause therapy Management of symptoms of PCOS Oncology supportive care product for Oral Mucositis Acquisition and in-licensing – ongoing 12 | www.biosyent.com | TSXV: RX
Slide 13: Cash Balance & Return on Equity
Cash Balance & Return on Equity (“RoE”) • Zero Debt 30,000 25% 27,899 27,923 21% • TTM Jun 30’24 Cash from 25,000 21% Operations of $2.5M 25,808 20% 16% 20,000 • TTM Jun 30’24 NCIB share 15% buybacks: $2.8 M 15,000 • 335,100 shares CAD (000's) RoE % 10% • TTM Jun’24 Net Dividends of 10,000 $2.0M 5%
Slide 14: Innovations and Product Launches
Innovations and Product Launches Tibella® Jul 2020 FeraMAX® Pd Oct 2020 FeraMAX® Pd Therapeutic 150 Nov 2020 Combogesic® Dec 2020 FeraMAX® Pd Powder 15 Oct 2021 FeraMAX® Pd Maintenance 45 Mar 2023 Inofolic® Aug 2023 Gelclair® Nov 2023 14 | www.biosyent.com | TSXV: RX
Slide 15: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification. • 8 new product launches in Canada since July 2020 Cash: Dividends $25.8M Growth & Diversification Debt: Share $0M Buybacks Excess capital may also be returned to shareholders: • Qua
Slide 16: Stock Information
Stock Information As at August 23, 2024 Exchange & Trading Symbol 0% TSXV: RX August 23, 2024 Closing Stock Price (CAD) (TSXV): $10.27 52 Week Hi/Low (TSXV): $10.75 / $7.45 Issued Common Shares: 11,791,299 Treasury – RSU Shares in Trust (204,385) RSUs funded Outstanding Common Shares: 11,586,914 wit
Slide 17: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 17 www.biosyent.com | TSXV: RX